Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Methimazole
Drug ID BADD_D01414
Description Methimazole is a thionamide antithyroid agent that inhibits the synthesis of thyroid hormones.[A184559,A184733,A184694] It was first introduced as an antithyroid agent in 1949[A184502] and is now commonly used in the management of hyperthyroidism, particularly in those for whom more aggressive options such as surgery or radioactive iodine therapy are inappropriate.[L8336,L8339] On a weight basis, methimazole is 10 times more potent than the other major antithyroid thionamide used in North America, [propylthiouracil],[L8339] and is the active metabolite of the pro-drug [carbimazole], which is an antithyroid medication used in the United Kingdom and parts of the former British Commonwealth.[A184733] Traditionally, methimazole has been preferentially used over propylthiouracil due to the risk of fulminant hepatotoxicity carried by the latter,[A184757] with propylthiouracil being preferred in pregnancy due to a perceived lower risk of teratogenic effects. Despite documented teratogenic effects in its published labels,[L8336,L8339] the true teratogenicity of methimazole appears to be unclear[A184643,A184757,A184763] and its place in therapy may change in the future.
Indications and Usage In the United States, methimazole is indicated for the treatment of hyperthyroidism in patients with Graves' disease or toxic multinodular goiter for whom thyroidectomy or radioactive iodine therapy are not appropriate treatment options. Methimazole is also indicated for the amelioration of hyperthyroid symptoms in preparation for thyroidectomy or radioactive iodine therapy.[L8336] In Canada, methimazole carries the above indications and is also indicated for the medical treatment of hyperthyroidism regardless of other available treatment options.[L8339]
Marketing Status approved
ATC Code H03BB02
DrugBank ID DB00763
KEGG ID D00401
MeSH ID D008713
PubChem ID 1349907
TTD Drug ID D0S4BR
NDC Product Code 63629-2225; 63629-8347; 70518-1506; 60687-357; 63629-2224; 63629-4331; 68788-8227; 72162-1803; 23155-070; 60429-381; 62135-206; 63629-6408; 63629-9137; 63629-9251; 64380-212; 64380-213; 54382-112; 62135-205; 63629-9249; 63629-9250; 62991-1515; 51927-1943; 49884-640; 70518-1475; 60687-669; 60687-680; 51552-0822; 33342-335; 60687-370; 64980-265; 68071-5197; 72162-1802; 66219-0253; 33342-336; 49884-641; 50090-6536; 64980-264; 68788-8226; 71335-0883; 38779-0360; 70160-001; 70600-032; 23155-071
UNII 554Z48XN5E
Synonyms Methimazole | 1-Methyl-2-mercaptoimidazole | 1 Methyl 2 mercaptoimidazole | Merkazolil | Tiamazol | Thiamazole | Thimazol | Mercasolyl | Mercazolyl | Methymazol | Methylmercaptoimidazole | Mercazol | Mercazole | Metisol | Metizol | Tapazole | Tirodril | Strumazol | Thiamazol Henning | Henning, Thiamazol | Thiamazol Hexal | Hexal, Thiamazol | Thyrozol | Favistan | Methizol
Chemical Information
Molecular Formula C4H6N2S
CAS Registry Number 60-56-0
SMILES CN1C=CNC1=S
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Premature baby18.04.02.0010.000809%Not Available
Premature delivery18.07.01.0060.000506%
Pruritus23.03.12.0010.001052%
Pulmonary alveolar haemorrhage24.07.01.015; 22.01.02.0050.000708%Not Available
Pyrexia08.05.02.0030.001416%
Rash23.03.13.0010.001699%Not Available
Rash erythematous23.03.13.0290.000202%Not Available
Rash macular23.03.13.0030.000202%Not Available
Rectal haemorrhage24.07.02.018; 07.12.03.001--
Renal tubular necrosis20.01.07.0030.000202%Not Available
Respiratory distress22.02.01.0120.000607%Not Available
Respiratory failure22.02.06.002; 14.01.04.0030.000405%
Reticulocytopenia01.07.02.0040.000202%Not Available
Retinal vasculitis10.02.02.021; 06.04.06.0110.000506%Not Available
Rhabdomyolysis15.05.05.0020.000708%
Serum sickness12.02.08.004; 10.01.03.0040.000506%
Somnolence19.02.05.003; 17.02.04.006--
Stevens-Johnson syndrome23.03.01.007; 12.03.01.014; 11.07.01.005; 10.01.01.0450.000303%
Systemic lupus erythematosus23.03.02.006; 15.06.02.003; 10.04.03.0040.000202%Not Available
Tachycardia02.03.02.0070.000202%Not Available
Thrombocytopenia01.08.01.0020.000405%Not Available
Thyrotoxic crisis05.02.02.004; 19.07.03.006; 14.11.01.016; 06.09.04.0040.001719%Not Available
Tonsillar hypertrophy22.04.05.0060.000202%Not Available
Urticaria23.04.02.001; 10.01.06.0010.000849%
Vasculitis24.12.04.027; 10.02.02.0060.000303%
Vertigo17.02.12.002; 04.04.01.003--
Vomiting07.01.07.003--
Lupus-like syndrome23.03.02.004; 15.06.02.004; 10.04.03.0030.000202%Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Pharyngeal erythema22.04.05.0100.000202%Not Available
The 4th Page    First    Pre   4 5    Next   Last    Total 5 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene